Core Viewpoint - The inclusion of the innovative drug Pyrotinib in the national medical insurance list is expected to enhance its affordability and accessibility for patients, positively impacting the company's long-term operational development [1] Group 1: Stock Performance - Xuan Bamboo Bio-B (02575) saw an early morning increase of over 6%, and as of the report, it rose by 2.36% to HKD 52.05, with a trading volume of HKD 2.99 million [1] Group 2: Drug Inclusion and Impact - Pyrotinib, a CDK4/6 inhibitor developed by the company, was successfully included in the national medical insurance drug list, effective January 1, 2026, providing new reimbursement benefits for patients with advanced breast cancer [1] - The company stated that the results of the medical insurance negotiations will help improve the drug's affordability and accessibility among patients, facilitating market promotion and increasing sales scale [1] - The company plans to actively cooperate in implementing the medical insurance policy, continue hospital access efforts, expand core markets, and enhance market coverage to improve patient access to the medication [1]
港股异动 | 轩竹生物-B(02575)早盘涨超6% 创新药吡洛西利2026元旦医保落地